Boston Scientific Corporation
AI Valuation
AI-generated fair value estimate for this company.
AI Fair Value
$61.81
Market Price
$42.42
Undervalued By
31.4%
Method: 10-year unlevered FCF DCF: $3.625B TTM free cash flow base; 10% annual FCF growth years 1-5 (post-2026 guidance-cut recovery, new product cycle); 6% years 6-10; 8.5% discount rate; 3% terminal growth; $12.085B net debt; 1.45B shares outstanding.
Reasoning: Boston Scientific is a profitable, diversified medtech franchise with durable historical double-digit growth and recurring device/procedure revenue, making a cash-flow DCF appropriate; near-term growth assumptions reflect the 2026 guidance cut and cyberattack-related disruption before a return toward historical mid-to-high single digit medtech growth.